SSWM
NBIX icon

Sheets Smith Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Sheets Smith Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,159
Closed -$297K – 390
2024
Q2 		$297K Buy
2,159
+101
+5% +$13.9K 0.04% 319
2024
Q1 		$284K Buy
2,058
+9
+0.4% +$1.23K 0.03% 324
2023
Q4 		$270K Buy
+2,049
New +$236K 0.04% 295
2020
Q1 		– Sell
-5,028
Closed -$536K – 306
2019
Q4 		$536K Buy
+5,028
New +$526K 0.1% 204

Other funds holding NBIX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return